Scholars Central

Conference abstractPublished 27 Jun 2016

Targeted delivery of generic chemotherapeutic agents to solid tumors via systemic nanotetrac (Nano-diamino-tetrac)

Authors: Paul J Davis

Albany College of Pharmacy and Health Sciences, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The principal secretory product of the thyroid gland, L-thyroxine (T4), is anti-apoptotic at physiological concentrations in a number of cancer cell lines. Among the mechanisms of anti-apoptosis activated by the hormone are interference with the Ser-15 phosphorylation (activation) of p53 and with TNFa/Fas-induced apoptosis. The hormone also decreases cellular abundance and activation of proteolytic caspases and of BAX and causes increased expression of X-linked inhibitor of apoptosis (XIAP). The anti-apoptotic effects of thyroid hormone largely are initiated at a cell surface thyroid hormone receptor on the extracellular domain of integrin avb3 that is amply expressed and activated in cancer cells. Tetraiodothyroacetic acid (tetrac) is a T4 derivative that, in a model of resveratrol-induced p53-dependent apoptosis in glioma cells, blocks the anti-apoptotic action of thyroid hormone, permitting specific serine phosphorylation of p53 and apoptosis to proceed. In a nanoparticulate formulation limiting its action to avb3, tetrac modulates integrin-dependent effects on gene expression in human cancer cell lines that include stimulation of expression of a panel of pro-apoptotic genes and downregulated transcription of defensive anti-apoptotic XIAP and MCL1 genes. By a variety of mechanisms, thyroid hormone (T4) acts as an endogenous anti-apoptotic factor that may oppose chemotherapy-induced apoptosis in avb3-expressing cancer cells. It is possible to oppose this anti-apoptotic activity pharmacologically by reducing circulating levels of T4 or by blocking effects of T4 that are initiated at avb3.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectOncology & Cancer
  • SubjectNanotechnology
  • BylineArticles whose byline prints “Paul J Davis”